prikaz prve stranice dokumenta Resistant and Relapsing Collapsing Glomerulopathy Successfully Treated with Rituximab—A Case Report
  Preuzmi
PDF 944.03 KB
Znanstveni rad - Prikaz slučaja
Resistant and Relapsing Collapsing Glomerulopathy Successfully Treated with Rituximab—A Case Report
Journal of Personalized Medicine, 12 (2022), 9; 1415. https://doi.org/10.3390/jpm12091415
Zagorec, Nikola; Klarić, Dragan; Klarić, Marta; Horvatić, Ivica; Šenjug, Petar; Horaček, Matija; Nikić, Jagoda; Galešić Ljubanović, Danica; Galešić, Krešimir

Citiranost:
,
Citirajte ovaj rad

Zagorec, N., Klarić, D., Klarić, M., Horvatić, I., Šenjug, P., Horaček, M. ... Galešić, K. (2022). Resistant and Relapsing Collapsing Glomerulopathy Successfully Treated with Rituximab—A Case Report. Journal of Personalized Medicine, 12. (9). doi: 10.3390/jpm12091415

Zagorec, Nikola, et al. "Resistant and Relapsing Collapsing Glomerulopathy Successfully Treated with Rituximab—A Case Report." Journal of Personalized Medicine, vol. 12, br. 9, 2022. https://doi.org/10.3390/jpm12091415

Zagorec, Nikola, Dragan Klarić, Marta Klarić, Ivica Horvatić, Petar Šenjug, Matija Horaček, Jagoda Nikić, Danica Galešić Ljubanović i Krešimir Galešić. "Resistant and Relapsing Collapsing Glomerulopathy Successfully Treated with Rituximab—A Case Report." Journal of Personalized Medicine 12, br. 9 (2022). https://doi.org/10.3390/jpm12091415

Zagorec, N., et al. (2022) 'Resistant and Relapsing Collapsing Glomerulopathy Successfully Treated with Rituximab—A Case Report', Journal of Personalized Medicine, 12(9). doi: 10.3390/jpm12091415

Zagorec N, Klarić D, Klarić M, Horvatić I, Šenjug P, Horaček M, i sur.. Resistant and Relapsing Collapsing Glomerulopathy Successfully Treated with Rituximab—A Case Report. Journal of Personalized Medicine [Internet]. 30.08.2022. [pristupljeno 14.03.2025.];12(9). doi: 10.3390/jpm12091415

N. Zagorec, et al., "Resistant and Relapsing Collapsing Glomerulopathy Successfully Treated with Rituximab—A Case Report", Journal of Personalized Medicine, vol. 12, br. 9, Kolovoz 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:366035. [Citirano: 14.03.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:366035
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Resistant and Relapsing Collapsing Glomerulopathy Successfully Treated with Rituximab—A Case Report
AutorNikola Zagorec
AutorDragan Klarić
AutorMarta Klarić
AutorIvica Horvatić
AutorPetar Šenjug
AutorMatija Horaček
AutorJagoda Nikić
AutorDanica Galešić Ljubanović
AutorKrešimir Galešić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA PATOLOGIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Patologija
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Collapsing glomerulopathy (CG) or collapsing focal segmental glomerulosclerosis (cFSGS) is an aggressive disease with a high tendency of progression to end-stage renal disease due to common resistance to conventional immunosuppressants. Rituximab (RTX), a monoclonal antibody against CD20 B cells, showed some benefit in the treatment of CG. We are reporting about female patients with an idiopathic form of CG presenting with nephrotic syndrome (NS) and renal insufficiency resistant to several... Više immunosuppressive agents such as steroids (ST), calcineurin inhibitors (CNI), and cyclophosphamide (CYC). This multidrug-resistant disease responded to RTX with complete remission. Forty-four months after initial RTX administration, a relapse of CG with severe NS and acute renal insufficiency occurred. Repeated application of RTX led to complete remission again. To the best of our knowledge, we are reporting the first case of the relapsing multidrug-resistant form of CG, which responded to RTX. Current data about the treatment of CG with RTX is lacking and is based on rare case reports and small case series. Thus, our report can contribute to determining the role of RTX in the treatment of CG. Sakrij dio sažetka
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Prikaz slučaja
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaJournal of Personalized Medicine
Brojčani podacivol. 12, br. 9, 1415
e-ISSN2075-4426
DOIhttps://doi.org/10.3390/jpm12091415
URN:NBNurn:nbn:hr:105:366035
Datum objave publikacije2022-08-30
URL dokumentahttps://www.mdpi.com/2075-4426/12/9/1415
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2023-02-10 10:32:44
accessibility

closePristupačnostrefresh

Ako želite spremiti trajne postavke, kliknite Spremi, ako ne - vaše će se postavke poništiti kad zatvorite preglednik.